Search Press releases Keywords From To 26 Apr 2024 Acquisition of own shares Read More 25 Apr 2024 UCB’s General Meeting of Shareholders 2024 Read More 25 Apr 2024 UCB off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus Read More 23 Apr 2024 Transparency notification FMR LLC Read More 22 Apr 2024 UCB receives European Commission approval for BIMZELX[®]▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa Read More 19 Apr 2024 Acquisition of own shares Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
